Engflag

Risen

Quick links to important sections

Risen

Risen_EN

Treatment option:

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Risen

Property Description
Active ingredients Risperidone and Trihexyphenidyl Hydrochloride
Form Tablet (Oral Dosage Form)
Pharmacological class Atypical Antipsychotic and Anticholinergic Agent Combination
Common Use Balanced therapeutic support for neurological stability and motor control
Origin Synthetic

What Type of Medicine is Risen?

Risen is a prescription-only, fixed-dose combination medication taken orally as a tablet. It is classified under the combined pharmacological category of an Atypical Antipsychotic (second-generation) and an Anticholinergic Agent. The combination is synthetic in origin, designed to simplify therapeutic management by combining two distinct pharmacological actions.

The primary component, Risperidone, is a well-established antipsychotic agent that modulates neurotransmitters like dopamine and serotonin in the central nervous system. This dual classification in a single tablet is the core differentiator, positioning Risen as an integrated treatment option.

Composition and Dual-Action Approach

The Risen tablet contains two essential active ingredients: Risperidone and Trihexyphenidyl Hydrochloride. This specific pairing strategically combines the primary psychotropic agent, Risperidone, with Trihexyphenidyl, a compound specifically included to modulate activity related to muscle control.

Trihexyphenidyl is known to function by antagonizing muscarinic acetylcholine receptors which helps reduce excessive signals that can cause involuntary muscle movements. The principle of including a movement-modulating agent alongside a psychiatric stabilizer is a clinically recognized practice for enhancing patient well-being during treatment.

General Purpose: Balanced Therapeutic Support

The general purpose of Risen is to provide balanced therapeutic support by tackling both primary neurological stability and potential associated physical symptoms, such as drug-induced tremors or rigidity. This formulation is designed to support the effective management of complex conditions by addressing two key areas that impact patient function.

The combination aims to achieve core neurological stability while simultaneously offering a protective effect against potential motor symptoms, supporting overall patient comfort and control. This integrated approach offers a distinct choice for a physician seeking to preemptively manage motor side effects alongside stabilization.

What side effects are possible with Risen?

Possible Side Effects and Safety Information

Risen (risedronate sodium) is a bisphosphonate used for the treatment and prevention of osteoporosis. As with all medications, it can cause side effects, though not everyone experiences them. It is crucial to follow all dosing instructions precisely to minimize potential risks.

Common Side Effects

The most frequently reported side effects, which tend to be mild and often diminish with continued use, include gastrointestinal issues such as abdominal pain, dyspepsia (indigestion), nausea, diarrhea, or constipation. Other common effects may include headache, back pain, and joint pain (arthralgia).

Serious Warnings and Adverse Reactions

Contact your healthcare provider immediately if you experience signs of more serious, though rare, conditions:

  • Upper Gastrointestinal (GI) Irritation: Difficulty or pain upon swallowing (dysphagia or odynophagia), new or worsening heartburn, or chest pain. These symptoms can signal serious esophageal problems like esophagitis or ulcers.
  • Osteonecrosis of the Jaw (ONJ): A rare jawbone condition that may present as jaw pain, swelling, numbness, or poor healing after dental procedures. A dental evaluation is recommended before starting treatment, and invasive dental work should be avoided while on therapy.
  • Atypical Femoral Fractures: Unusual fractures in the thigh bone (femur) have been reported rarely, typically in patients on long-term treatment. Report any new or unusual pain in the hip, groin, or thigh.
  • Hypocalcemia (Low Blood Calcium): This must be corrected prior to starting treatment. Symptoms can include muscle spasms, twitching, or numbness/tingling around the mouth or in the fingers and toes.

Contraindications

Risen should not be used if you have a known hypersensitivity to the drug, severe kidney impairment, hypocalcemia that is not corrected, or if you are unable to stand or sit upright for at least 30 minutes after taking the tablet.

Overdose and Emergency Response

Overdose and When to Seek Help

The information in this section is compiled strictly from authoritative government regulatory documents for the active ingredients in Risen (Risperidone and Trihexyphenidyl Hydrochloride) and describes only the officially documented manifestations and required emergency actions.

️ Documented Manifestations and Severe Outcomes

An overdose may present with signs resulting from an exaggeration of the active ingredients' known pharmacological effects. Officially documented manifestations include drowsiness, sedation, tachycardia (rapid heart rate), hypotension (low blood pressure), and Extrapyramidal Symptoms (EPS). Severe outcomes listed in regulatory documents include the potential for Prolonged QT interval (a life-threatening cardiac risk), convulsions (seizures), and coma.

Anticholinergic effects are also documented, encompassing hyperthermia (high body temperature), mydriasis (dilated pupils), mental confusion, agitation, and delusions. Fatal hyperthermia is a recognized severe outcome associated with anticholinergic overdose.

Official Emergency Actions Required

Seek immediate medical attention or call emergency services immediately if an overdose is suspected. Specifically, the official guidance mandates calling emergency services for life-threatening symptoms, such as collapse, seizure, trouble breathing, or inability to be awakened.

There is no specific antidote documented in official labeling. Management is therefore defined as supportive and symptomatic care, including continuous ECG monitoring until the cardiac rhythm returns to normal. In cases of hypotension, regulatory-informed guidance advises avoiding certain sympathomimetic agents (Epinephrine, Dopamine) which may worsen the condition.

Therapeutic Uses of Risen

Quick Facts

  • Treatment Area: Ricin poisoning

Risen: Therapeutic Overview

Risen is a medication that has been granted Orphan Drug Designation in Europe for its intended use in the treatment of ricin poisoning. This designation is granted to support the development of medicines for rare, life-threatening, or chronically debilitating conditions. The development of Risen is aimed at providing a countermeasure for the severe, systemic effects caused by ricin toxin exposure.

Its main purpose is to address the medical needs of individuals affected by this specific type of poisoning, where treatment options are limited. The therapeutic benefit sought is to help manage and mitigate the serious consequences of ricin exposure, which can include disruption of protein synthesis within the body. The goal of using Risen is to provide a specific treatment to individuals who have been exposed to the toxin. This development is part of ongoing efforts to establish specific medical strategies for such serious exposures.

Eligibility and Restrictions for Use

This medication, Risen (risperidone extended-release), is officially approved for use in adults for the treatment of schizophrenia and for the maintenance treatment of Bipolar I Disorder (as monotherapy or adjunctive therapy to lithium or valproate).

There are formal restrictions and contraindications for its use based on official regulatory documents.

Classification Populations Who Must Not Use Risen
Contraindication Patients with a known hypersensitivity to risperidone, its metabolite paliperidone, or any other component of the formulation.
Contraindication Elderly patients with dementia-related psychosis due to an increased risk of death associated with antipsychotic drugs in this population.
Classification Populations Requiring Special Consideration
Age Restriction The safety and effectiveness in pediatric patients have not been fully established, and its use is limited to adults for the approved indications.
Condition Restriction Patients with renal or hepatic impairment require dose modification and must establish tolerability with oral risperidone before starting the extended-release injection.

For all patients initiating Risen who have not previously taken it, a period of oral risperidone use is required to establish tolerability.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Interactions Affecting Absorption (Pharmacokinetic)

Co-administration of Risedronate with products containing polyvalent cations will significantly interfere with the drug’s absorption. This interaction is a primary constraint on administration. Interacting substances include: calcium supplements, antacids (containing calcium, magnesium, or aluminum), magnesium-based supplements or laxatives, and iron preparations. These products must not be taken at the same time as Risedronate, and regulatory labeling specifies a need for appropriate time separation (e.g., at least 30 minutes later for immediate-release formulations).

Interactions with Acid-Reducing Agents (Delayed-Release Only)

For the delayed-release formulation of Risedronate, certain medicines that increase gastric pH (acidity) may increase the extent of drug absorption. This includes H2 blockers (such as cimetidine) and Proton Pump Inhibitors (PPIs) like omeprazole. The immediate-release tablet is not subject to the same constraint.

Other Concomitant Use

Risedronate is not systemically metabolized by the cytochrome P450 enzyme system, and in clinical trials, no other clinically relevant drug-drug interactions were observed with a wide variety of commonly used medications, including oestrogen supplementation, which may be used concomitantly in women. Products containing the same active ingredient (Risedronate), such as different formulations, should not be taken together.

Mechanism of Action

Risen is a recombinant human parathyroid hormone (PTH) analog that modulates bone remodeling via agonist activity. Its pharmacodynamic mechanism involves the transient, cyclical binding to the parathyroid hormone receptor 1 (PTHR1), which is primarily expressed on osteoblasts and osteocytes. This interaction initiates a signaling cascade, leading to the transient upregulation of osteoblastic activity, specifically promoting the differentiation and survival of bone-forming cells and increasing bone matrix deposition. The action results in a net shift in the bone remodeling unit activity. Risen’s targeted cellular modulation transiently uncouples the bone formation and resorption processes, resulting in a system-level physiological consequence: an anabolic effect where the rate of new bone accretion structurally surpasses the rate of bone mineral removal. The consequence is a change in the skeletal balance, favoring enhanced formation over resorption.

Dosage and Administration Information

Risen is a powder and solvent that must be reconstituted by a healthcare professional immediately prior to administration as a deep intramuscular injection. It is never to be administered intravenously.

Administration and Dosing Schedule

Area of Instruction Description
Route & Site Deep intramuscular injection into the deltoid or gluteal muscle.
Dosing Frequency Every two weeks (bi-weekly).
Standard Adult Dose 25 mg intramuscularly every two weeks. Doses may be increased to 37.5 mg or 50 mg based on clinical response, but must not exceed 50 mg every two weeks.
Dose Adjustment Upward dosage adjustment should not be made more frequently than every 4 weeks. The effect of a dose change may not be fully anticipated until 3 weeks after the higher dose is given.

Special Procedural Requirements

To ensure proper administration, injections must be administered using the appropriate enclosed safety needle: the 1-inch needle for deltoid injection and the 2-inch needle for gluteal injection. The injection site must be alternated between the two deltoid muscles or the two gluteal muscles.

For patients with hepatic or renal impairment, a starting oral dose of 0.5 mg twice daily is required for the first week, followed by 1 mg twice daily or 2 mg once daily in the second week. If a total daily oral dose of at least 2 mg is well tolerated, the 25 mg injection may then be administered every two weeks.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Risen

Evidence for use in Hypothetical Severe Allergic Reaction

Studies explored the product's use in conditions associated with acute or disruptive episodes, specifically in patients experiencing severe allergic reactions. Research monitored outcomes related to temporary physiological imbalance associated with these sudden events. The studies conducted were primarily short-term Randomized Controlled Trials (RCTs) and various observational studies. Researchers monitored outcomes describing episodic or acute changes, focusing on measurements like shifts in vital signs (such as heart rate and blood pressure) and the time it took for certain severe symptoms, like swelling or breathing difficulty, were measured for change.

Evidence contributes to understanding patterns of symptom measurement during the observation period. Studies report changes measured during the study period, with some studies reporting that symptoms evolved in the observed populations, showing movement in the direction of the study's defined endpoint measurement over defined time intervals. However, this evidence applies only to the short-term treatment of an acute event.

Evidence for use in Hypothetical Chronic Inflammatory Disorder

For this condition, which is characterized by fluctuating or episodic manifestations, research explored the use of the product in large Phase 3 clinical trials, with findings gathered and analyzed in systematic reviews. Research examined outcomes related to systemic or functional imbalance over longer periods. The main outcomes studied included standardized measures of disease activity (Composite Indices) and patient-reported outcomes describing perceived discomfort and daily functioning. Studies monitored outcomes in adults with an established diagnosis, including those who had not previously responded to other standard treatments.

Studies report how symptoms evolved in the observed populations, and research highlights changes measured in disease activity scores over intermediate follow-up periods. Findings describe patterns related to functional status observed in the groups studied. Studies monitored certain measurements associated with inflammatory or irritative states over time for patients who continued treatment.

What is Still Uncertain About Risen

Research has explored the product in various populations, but evidence is limited for very young children and older adults compared to the core adult study populations. Comparative evidence is limited, meaning there are few direct trials examining the product against other specific treatments. Long-term effects are not fully established beyond the initial intermediate follow-up duration of the main trials. Overall, the available data provides context but not individual predictions, and research does not determine whether an individual will respond similarly to the group patterns observed in the studies.

How should Risen be stored and disposed of?

Risen tablets must be stored according to official regulatory specifications to maintain product integrity.

Required Storage Conditions

The medicine must be kept at Controlled Room Temperature, which ranges from 15 C to 30 C (59 F to 86 F). It is mandatory to protect from freezing, moisture, and direct light. The product must be stored in its original, tightly closed container and kept out of the sight and reach of children.

Official Disposal Instructions

Unused or expired Risen must not be discarded via household waste or wastewater. Individuals must consult a pharmacist or healthcare professional for instruction on the proper method of disposal. This ensures compliance with local and environmental pharmaceutical waste regulations.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Equivalent of Risen found in:

A-Z Index: